Maraviroc (brand-named Selzentry, or Celsentri outside the U.S.) is a chemokine receptor antagonist drug developed by the drug company Pfizer that is designed to act against HIV by interfering with the interaction between HIV and CCR5. It was originally labelled as UK-427857 during development but was assigned the Maraviroc name as it entered trials. It was ...
Maraviroc is indicated in combination with other antiretroviral agents for the treatment of CCR5-tropic HIV-1 infection in adults and pediatric patients weighing at least 2kg. It is not recommended in patients with dual/mixed- or CXCR4-tropic HIV-1.
NIH/NIAD, Bethesda, Maryland, United States
Hospital General de León, Leon, Guanajuato, Mexico
HIV-1 Immunopathogenesis Laboratory. The Wistar Institute, Philadelphia, Pennsylvania, United States
Imperial College Healthcare NHS Trust, London, United Kingdom
Imperial College Healthcare NHS Trust, London, United Kingdom
Cork University Hospital, Cork, Ireland
Mater Misericordiae University Hospital, Dublin, Ireland
Germans Trias i Pujol Hospital, Badalona, Barcelona, Spain
Lluita contra la Sida Foundation, HIV Unit, Badalona, Barcelona, Spain
Lluita contra la Sida Foundation, HIV Unit, Irsi Caixa Foundation, Badalona, Barcelona, Spain
French National Agency for Research on AIDS and Viral Hepatits, Paris, France
Harbor-UCLA, Torrance, California, United States
University California San Diego, San Diego, California, United States
University Southern California, Los Angeles, California, United States
Servizio Regionale di Immunologia Clinica e Tipizzazione Tissutale, Azienda Ospedaliero-Universitaria, Torrette di Ancona, AN, Italy
Clinica di Malattie Infettive, Policlinico, Universita' degli Studi, Bari, BA, Italy
Clinica di Malattie Infettive e Tropicali, Università degli Studi di Brescia, Spedali civili, Brescia, BS, Italy
Erasmus MC, Rotterdam, Netherlands
Sint Elisabeth Ziekenhuis, Tilburg, Netherlands
Academisch Medisch Centrum (AMC), Amsterdam, Netherlands
Pfizer Investigational Site, Bruxelles, Belgium
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.